Qurient Co., Ltd. (115180.KQ)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ki-Yean Nam | CEO, CSO & Chairman | -- | -- | 1971 |
| Mr. Chang Eyun Yu | Chief Financial Officer | -- | -- | -- |
| Mr. Choi Kiwon | Chief Operating Officer | -- | -- | -- |
| Dr. Kim Jae-Seung | Chief Technology Officer | -- | -- | 1968 |
| Ms. Hyunjin Lim | Senior Vice President of Management Administration Officer | -- | -- | -- |
| Dr. Joongsik Hwang | Director | -- | -- | -- |
| Dr. Seung-Joo Lee | Senior Vice President of Pharmacology | -- | -- | -- |
Qurient Co., Ltd.
Description
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.
Corporate Governance
Recent Events
Recent Events Information Not Available